MEA
MCID: MLT074
MIFTS: 56

Multiple Endocrine Neoplasia (MEA) malady

Categories: Cancer diseases, Genetic diseases, Rare diseases, Gastrointestinal diseases, Endocrine diseases, Neuronal diseases

Aliases & Classifications for Multiple Endocrine Neoplasia

Aliases & Descriptions for Multiple Endocrine Neoplasia:

Name: Multiple Endocrine Neoplasia 25 52 69
Endocrine Neoplasia, Multiple 25 29
Multiple Endocrine Neoplasia Type 1 69
Adenomatosis, Familial Endocrine 25
Multiple Endocrine Adenomatosis 25
Familial Endocrine Adenomatosis 25
Multiple Endocrine Neoplasms 25
Mea 25
Men 25

Classifications:



Summaries for Multiple Endocrine Neoplasia

Genetics Home Reference : 25 Multiple endocrine neoplasia is a group of disorders that affect the body's network of hormone-producing glands called the endocrine system. Hormones are chemical messengers that travel through the bloodstream and regulate the function of cells and tissues throughout the body. Multiple endocrine neoplasia typically involves tumors (neoplasia) in at least two endocrine glands; tumors can also develop in other organs and tissues. These growths can be noncancerous (benign) or cancerous (malignant). If the tumors become cancerous, the condition can be life-threatening.

MalaCards based summary : Multiple Endocrine Neoplasia, also known as endocrine neoplasia, multiple, is related to zollinger-ellison syndrome and gastrinoma, and has symptoms including diarrhea An important gene associated with Multiple Endocrine Neoplasia is RET (Ret Proto-Oncogene), and among its related pathways/superpathways are Neuroscience and Signaling events regulated by Ret tyrosine kinase. The drugs Zinc and Progesterone have been mentioned in the context of this disorder. Affiliated tissues include thyroid, pituitary and testes, and related phenotypes are Decreased viability and cardiovascular system

Wikipedia : 71 The term multiple endocrine neoplasia (MEN) encompasses several distinct syndromes featuring tumors of... more...

Related Diseases for Multiple Endocrine Neoplasia

Diseases in the Multiple Endocrine Neoplasia family:

Multiple Endocrine Neoplasia Iia Multiple Endocrine Neoplasia Iib
Multiple Endocrine Neoplasia 1 Multiple Endocrine Neoplasia, Type Iv

Diseases related to Multiple Endocrine Neoplasia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 199)
id Related Disease Score Top Affiliating Genes
1 zollinger-ellison syndrome 31.1 CHGA NF1 RET SDHB SDHC VHL
2 gastrinoma 31.0 CALCA RET
3 pheochromocytoma 30.3 CALCA CHGA GDNF MEN1 NF1 PNMT
4 parathyroid carcinoma 29.8 CALCA CHGA MEN1 PRKAR1A RET
5 gastrointestinal stromal tumor 29.1 CHGA NF1 SDHB SDHC
6 aneurysm 27.2 CALCA CDKN1B CHGA GDNF MEN1 NF1
7 multiple endocrine neoplasia 1 12.7
8 multiple endocrine neoplasia iia 12.7
9 multiple endocrine neoplasia iib 12.6
10 multiple endocrine neoplasia, type iv 12.5
11 insulinoma 11.4
12 acromegaly 11.3
13 vipoma 11.3
14 gigantism 11.3
15 medullary thyroid carcinoma, familial 11.3
16 pancreatic cholera 11.3
17 pituitary adenoma, prolactin-secreting 11.1
18 pituitary adenoma, growth hormone-secreting 11.0
19 adrenal carcinoma 11.0
20 pituitary adenoma, acth-secreting 11.0
21 thyroiditis 10.7
22 hyperparathyroidism 10.6
23 pancreatitis 10.5
24 neuroendocrine tumor 10.4
25 adenoma 10.3
26 pemphigus foliaceus 10.3 CALCA MEN1
27 paranasal sinus cancer, adult 10.3 CALCA MEN1
28 meigel disease 10.3 GDNF RET
29 hyperparathyroidism, familial primary 10.3 MEN1 RET
30 amyloidosis 10.3
31 early-onset parkinson disease 10.2 MEN1 RET
32 hypoparathyroidism-intellectual disability-dysmorphism syndrome 10.2 GDNF RET
33 lichen amyloidosis 10.2
34 pancreatic neuroendocrine tumor 10.2
35 atrial heart septal defect 10.2 CALCA NF1
36 brain ependymoma 10.2 CALCA NF1
37 neuroma 10.2
38 uterine ligament cancer 10.2 MEN1 PRKAR1A
39 phaeochromocytoma 10.2
40 perineural angioma 10.2 CALCA CHGA
41 opioid abuse 10.2 CALCA MEN1 RET
42 trombiculiasis 10.2 CHGA NF1
43 pituitary adenoma 10.2
44 thyroid cancer 10.2
45 parietal lobe neoplasm 10.2 CALCA CHGA
46 peritoneal serous papillary adenocarcinoma 10.2 CALCA CDKN1B RET
47 volkmann contracture 10.2 CALCA CHGA
48 connective tissue cancer 10.1 CALCA GDNF RET
49 childhood vagina botryoid rhabdomyosarcoma 10.1 CALCA NF1
50 cowper gland carcinoma 10.1 CHGA MEN1 RET

Graphical network of the top 20 diseases related to Multiple Endocrine Neoplasia:



Diseases related to Multiple Endocrine Neoplasia

Symptoms & Phenotypes for Multiple Endocrine Neoplasia

UMLS symptoms related to Multiple Endocrine Neoplasia:


diarrhea

GenomeRNAi Phenotypes related to Multiple Endocrine Neoplasia according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00221-A-1 9.81 PRKAR1A RET VHL CDKN1B NF1
2 Decreased viability GR00221-A-2 9.81 NF1 PRKAR1A RET VHL
3 Decreased viability GR00221-A-3 9.81 PRKAR1A
4 Decreased viability GR00221-A-4 9.81 NF1 PRKAR1A RET
5 Decreased viability GR00231-A 9.81 RET
6 Decreased viability GR00301-A 9.81 RET VHL
7 Decreased sensitivity to paclitaxel GR00112-A-0 8.96 VHL NF1

MGI Mouse Phenotypes related to Multiple Endocrine Neoplasia:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.16 PNMT CHGA PRKAR1A GDNF RET MEN1
2 endocrine/exocrine gland MP:0005379 10.02 CHGA PRKAR1A GDNF RET MEN1 SDHB
3 mortality/aging MP:0010768 10.02 CHGA PRKAR1A GDNF RET MEN1 CDKN1B
4 digestive/alimentary MP:0005381 9.95 PRKAR1A GDNF RET MEN1 CDKN1B NF1
5 craniofacial MP:0005382 9.83 NF1 CDKN1B PRKAR1A MEN1 VHL
6 muscle MP:0005369 9.8 PRKAR1A GDNF RET MEN1 CDKN1B NF1
7 neoplasm MP:0002006 9.7 PRKAR1A RET MEN1 CDKN1B NF1 SDHB
8 renal/urinary system MP:0005367 9.43 CDKN1B NF1 CHGA GDNF RET VHL
9 reproductive system MP:0005389 9.17 CDKN1B CHGA PRKAR1A GDNF RET MEN1

Drugs & Therapeutics for Multiple Endocrine Neoplasia

Drugs for Multiple Endocrine Neoplasia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 570)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Zinc Approved Phase 4,Phase 3,Early Phase 1 7440-66-6 32051 23994
2
Progesterone Approved, Vet_approved Phase 4,Phase 3,Phase 2 57-83-0 5994
3
Epinephrine Approved, Vet_approved Phase 4,Phase 2,Phase 1 51-43-4 5816
4
Metformin Approved Phase 4,Phase 3,Phase 2 657-24-9 14219 4091
5
Hydrocortisone Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 50-23-7 5754 657311
6
Letrozole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 112809-51-5 3902
7
Cortisone acetate Approved Phase 4 1950-04-4, 50-04-4 5745
8
Sunitinib Approved, Investigational Phase 4,Phase 2 341031-54-7, 557795-19-4 5329102
9
Dopamine Approved Phase 4,Phase 3,Phase 2 51-61-6, 62-31-7 681
10
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 50-02-2 5743
11
Diazepam Approved, Illicit, Vet_approved Phase 4,Phase 1 439-14-5 3016
12
Simvastatin Approved Phase 4 79902-63-9 54454
13
Tacrolimus Approved, Investigational Phase 4,Phase 2 104987-11-3 445643 439492
14
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 50-28-2 5757 53477783
15
Iron Approved Phase 4,Phase 3 7439-89-6 23925
16
Morphine Approved, Investigational Phase 4 57-27-2 5288826
17
Octreotide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 83150-76-9 383414 6400441
18
Histamine Approved, Investigational Phase 4,Phase 1 75614-87-8, 51-45-6 774
19
Drospirenone Approved Phase 4 67392-87-4 68873
20
Infliximab Approved Phase 4 170277-31-3
21
Cabergoline Approved Phase 4,Phase 3 81409-90-7 54746
22
Prednisolone Approved, Vet_approved Phase 4,Phase 2 50-24-8 5755
23
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1 22916-47-8 4189
24
Leuprolide Approved, Investigational Phase 4 53714-56-0 3911 657181
25
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
26
Anastrozole Approved, Investigational Phase 4,Phase 3,Phase 2 120511-73-1 2187
27
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
28
Everolimus Approved Phase 4,Phase 2,Phase 1 159351-69-6 6442177
29
Vancomycin Approved Phase 4 1404-90-6 441141 14969
30
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
31
Liraglutide Approved Phase 4,Phase 3 204656-20-2
32
Modafinil Approved, Investigational Phase 4 68693-11-8 4236
33
Hydroxocobalamin Approved Phase 4,Phase 2 13422-51-0 11953898 5460373 44475014
34
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2 83-43-2 6741
35
Ethinyl Estradiol Approved Phase 4,Phase 3 57-63-6 5991
36
Insulin Glargine Approved Phase 4 160337-95-1
37
Olaparib Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 763113-22-0 23725625
38
Armodafinil Approved, Investigational Phase 4 112111-43-0
39
Sirolimus Approved, Investigational Phase 4,Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
40
Menotropins Approved Phase 4,Phase 1,Phase 2 61489-71-2 5360545
41
Insulin Lispro Approved Phase 4 133107-64-9
42
Somatostatin Approved Phase 4,Phase 3,Phase 2 38916-34-6, 51110-01-1 53481605
43
Toremifene Approved, Investigational Phase 4 89778-26-7 3005573
44
Mycophenolic acid Approved Phase 4,Phase 2 24280-93-1 446541
45
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 2 128794-94-5 5281078
46
Basiliximab Approved, Investigational Phase 4,Phase 2 152923-56-3, 179045-86-4
47
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
48
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 59-30-3 6037
49
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 58-05-9 54575, 6560146 143
50
Manganese Approved, Nutraceutical Phase 4 7439-96-5 27854

Interventional clinical trials:

(show top 50) (show all 785)
id Name Status NCT ID Phase
1 rAd-p53 Gene Therapy for Advanced Malignant Thyroid Tumors Unknown status NCT00902122 Phase 4
2 Assessment Of Gh-Igf-1 Axis In Children With Chronic Myelogenous Leukemia (CML) In Remission Unknown status NCT01901666 Phase 4
3 Dual RElease Hydrocortisone Versus conventionAl Glucocorticoid replaceMent Therapy in Hypocortisolism (DREAM) Unknown status NCT02277587 Phase 4
4 Strategies for Ovulation Induction in Anovulatory Infertile Patients With PCOS Unknown status NCT00461643 Phase 4
5 Surgical Ovarian Drilling Versus Hormonal Treatment for Infertility Associated to PolyCystic Ovaries Syndrome (PCOS) Unknown status NCT00378729 Phase 4
6 Myoinositol for the Treatment of Ovarian and Psychiatric Disorder in Polycystic Ovary Syndrome (PCOS) Patients Unknown status NCT01246310 Phase 4
7 Vancomycin Associated Red Man Syndrome (RMS) Completed NCT00824122 Phase 4
8 Treatment of Zollinger-Ellison Syndrome With Prevacid Completed NCT00204373 Phase 4
9 RCT: Difference in Diagnostic Yield Between EUSFNA Needles With and Without a Side Port in Pancreatic Masses Completed NCT02092519 Phase 4
10 Comparing Covered Self-expandable Metallic Stent (SEMS) Above/Across the Sphincter of Oddi Completed NCT01041612 Phase 4
11 Percutaneous Laser Ablation in Benign Thyroid Nodules.Long Term Results Completed NCT00858104 Phase 4
12 Randomized Clinical Trial of Posterior Retroperitoneoscopic Adrenalectomy Versus Lateral Laparoscopic Adrenalectomy Completed NCT01959711 Phase 4
13 Effect of 5 Years of GH Replacement on Atherosclerosis Completed NCT00462475 Phase 4
14 Cardiac Valve Complications in Prolactinomas Treated With Cabergoline Completed NCT00460616 Phase 4
15 A Study of Infliximab for Treatment Resistant Major Depression Completed NCT00463580 Phase 4
16 Antinociceptive Modalities on Ischemia Reperfusion Injury Completed NCT01932918 Phase 4
17 An Eight Week, Double-Blind Efficacy Study of Armodafinil Augmentation to Alleviate Fibromyalgia Fatigue Completed NCT00678691 Phase 4
18 Clinical, Metabolic and Endocrine Effects of the Treatment With Drospirenone and Ethinyl Estradiol Alone or in Combination With Myo-inositol in Young Women With Polycystic Ovary Syndrome (PCOS) and Insulin Resistance Completed NCT01511822 Phase 4
19 Myo-inositol Versus D-chiro-inositol in the Treatment of Polycystic Ovary Syndrome and Insulin Resistance: Evaluation of Clinical, Metabolic, Endocrine and Ultrasound Parameters Completed NCT01514942 Phase 4
20 A Phase 4 Study to Determine Dosing of Hectorol® Capsules When Converting From Zemplar® Injection Completed NCT00463021 Phase 4
21 Glargine Versus NPH in Patients With Chronic Kidney Disease Completed NCT02451917 Phase 4
22 Efficacy and Safety of 6 Months Treatment With Paricalcitol Injection or Oral in Patients With Secondary Hyperparathyroidism on Dialysis Completed NCT00537979 Phase 4
23 Study of Safety and Efficacy of Doxercalciferol in Patients With Chronic Kidney Disease, Stage 3 or 4, and Secondary Hyperparathyroidism Completed NCT00123461 Phase 4
24 Paricalcitol Versus Calcitriol for Efficacy and Safety in Stage 3/4 Chronic Kidney Disease (CKD) With Secondary Hyperparathyroidism (SHPT) Completed NCT00823303 Phase 4
25 Letrozole Versus Clomifene Citrate for Ovulation Induction Completed NCT00478504 Phase 4
26 Menopur® Versus Follistim® in Polycystic Ovarian Syndrome (PCOS) Completed NCT00805935 Phase 4
27 PCOSMIC Trial - PolyCystic Ovary Syndrome, Metformin for Infertility With Clomiphene Completed NCT00795808 Phase 4
28 Body Composition, Glucose Metabolism, Insulin Resistance and Gene Expression in Muscle Cells in Healthy Overweight Women Completed NCT00145392 Phase 4
29 The Effects of Vitamin D on Transforming Growth Factor-beta1 in Polycystic Ovary Syndrome Completed NCT02460380 Phase 4
30 Effects of Metformin Plus Simvastatin on Polycystic Ovarian Syndrome (PCOS): A Prospective, Randomized, Double-Blind, Placebo-Controlled Study Completed NCT01021579 Phase 4
31 Metformin in High Responder Polycystic Ovary Syndrome (PCOS) Patients Undergoing IVF Cycles Completed NCT01233206 Phase 4
32 Effect and Safety of Oral Vancomycin in Primary Sclerosing Cholangitis Patients Recruiting NCT02605213 Phase 4
33 Adjuvant Endocrine Therapy for Estrogen Receptor-beta Positive Triple Negative Breast Cancer Recruiting NCT02089854 Phase 4
34 Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly Recruiting NCT02060383 Phase 4
35 Preoperative Biliary Drainage in Resectable Pancreatic or Periampullary Cancer Recruiting NCT01774019 Phase 4
36 Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China Recruiting NCT02842749 Phase 4
37 Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study. Recruiting NCT01794793 Phase 4
38 To Assess the Efficacy and Safety of Olaparib Maintenance Monotherapy in the Treatment of Ovarian Cancer Recruiting NCT02476968 Phase 4
39 Oral Iron vs. Placebo in Newly Diagnosed Gynecologic Oncology Patients Who Are Surgical Candidates. Recruiting NCT01953107 Phase 4
40 Trial of Steroid Avoidance and Low-dose CNI by ATG-induction in Renal Transplantation Recruiting NCT02083991 Phase 4
41 Extended Use of Recombinant Human Parathyroid Hormone (rhPTH(1-84)) in Hypoparathyroidism Recruiting NCT02910466 Phase 4
42 Clinical Effectiveness of Serum Chromogranin A Levels on Diagnostic of Pancreatic Neuroendocrine Tumors Active, not recruiting NCT02759718 Phase 4
43 A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors Active, not recruiting NCT01525550 Phase 4
44 Efficacy and Safety of Cinacalcet in Ca, P and iPTH Levels in Patients With Mild, Moderate and Severe SHPT Not yet recruiting NCT03123406 Phase 4
45 Controlled Ovarian Stimulation Followed by Timed Intercourse or Intrauterine Insemination in Infertile PCOS Patients Suspended NCT00502281 Phase 4
46 Study Assessing the Efficacy and Safety of Octreotide Acetate in Patients With Acromegaly, With Micro or Macroadenomas Terminated NCT00242541 Phase 4
47 Effect of Cetrorelex Acetate on Ovarian Function in Women Undergoing Chemotherapy Withdrawn NCT00507780 Phase 4
48 Clomiphene Citrate in Infertile PCOS Patients Withdrawn NCT00501839 Phase 4
49 Therapy for Infertile PCOS Patients Ovulating Under Clomiphene Citrate or Metformin Withdrawn NCT00502229 Phase 4
50 Effect of Progestin-Induced Withdrawal Bleed on Ovulation Induction Cycles With Clomiphene Citrate Withdrawn NCT01966575 Phase 4

Search NIH Clinical Center for Multiple Endocrine Neoplasia

Genetic Tests for Multiple Endocrine Neoplasia

Genetic tests related to Multiple Endocrine Neoplasia:

id Genetic test Affiliating Genes
1 Multiple Endocrine Neoplasia 29

Anatomical Context for Multiple Endocrine Neoplasia

MalaCards organs/tissues related to Multiple Endocrine Neoplasia:

39
Thyroid, Pituitary, Testes, Bone, Pancreas, Skin, Prostate

Publications for Multiple Endocrine Neoplasia

Articles related to Multiple Endocrine Neoplasia:

(show top 50) (show all 1136)
id Title Authors Year
1
Evidence for the founder effect of RET533 as the common Greek and Brazilian ancestor spreading multiple endocrine neoplasia 2A. ( 28137737 )
2017
2
Growth rate of small pancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1: results from an endoscopic ultrasound based cohort study. ( 27975336 )
2017
3
Lung adenocarcinoma and adrenocortical carcinoma in a patient with multiple endocrine neoplasia type 1. ( 28070481 )
2017
4
Long-term outcomes in patients with multiple endocrine neoplasia type 1 and pancreaticoduodenal neuroendocrine tumours. ( 27770475 )
2017
5
Unilateral Clearance for Primary Hyperparathyroidism in Selected Patients with Multiple Endocrine Neoplasia Type 1: Reply. ( 27847968 )
2017
6
Different RET gene mutation-induced multiple endocrine neoplasia type 2A in 3 Chinese families. ( 28099363 )
2017
7
Operative intervention for primary hyperparathyroidism offers greater bone recovery in patients with sporadic disease than in those with multiple endocrine neoplasia type 1-related hyperparathyroidism. ( 27842919 )
2017
8
Composite paraganglioma-ganglioneuroma concomitant with adrenal metastasis of medullary thyroid carcinoma in a patient with multiple endocrine neoplasia type 2B: A case report. ( 27704704 )
2017
9
Distribution of RET Mutations in Multiple Endocrine Neoplasia 2 in Denmark 1994-2014: A Nationwide Study. ( 27809725 )
2017
10
Multiple endocrine neoplasia type 1 associated with a new germline Men1 mutation in a family with atypical tumor phenotype. ( 26732163 )
2016
11
A Nationwide Study of Multiple Endocrine Neoplasia Type 2A in Norway: Predictive and Prognostic Factors for the Clinical Course of Medullary Thyroid Carcinoma. ( 27400880 )
2016
12
A novel in-frame deletion in MEN1 (p.Ala416del) causes familial multiple endocrine neoplasia typeA 1 with an aggressive phenotype and unexpected inheritance pattern. ( 27430871 )
2016
13
A rare missense variant in RET exon 8 in a Portuguese family with atypical multiple endocrine neoplasia type 2A. ( 27838608 )
2016
14
Recurrence of phaeochromocytoma in pregnancy in a patient with multiple endocrine neoplasia 2A: a case report and review of literature. ( 27808580 )
2016
15
Minimally Invasive Versus Open Pancreatic Surgery in Patients with Multiple Endocrine Neoplasia Type 1. ( 26956903 )
2016
16
A rare presentation of multiple endocrine neoplasia (MEN) type 2A syndrome. ( 26858832 )
2016
17
In Response to the Article Entitled "Unilateral Clearance for Primary Hyperparathyroidism in Selected Patients with Multiple Endocrine Neoplasia Type 1". ( 27646283 )
2016
18
SOS1 frameshift mutations cause pure mucosal neuroma syndrome, a clinical phenotype distinct from multiple endocrine neoplasia type 2B. ( 26708403 )
2016
19
Generation of an induced pluripotent stem cell line from a patient with hereditary multiple endocrine neoplasia 2A (MEN2A) syndrome with RET mutation. ( 27558615 )
2016
20
Corneal xanthogranuloma in association with multiple endocrine neoplasia 1: A clinicopathologic case report and review of the literature. ( 26949359 )
2016
21
Utility of chromogranin A, pancreatic polypeptide, glucagon and gastrin in the diagnosis and follow-up of pancreatic neuroendocrine tumours in multiple endocrine neoplasia type 1 patients. ( 27256431 )
2016
22
Multiple Endocrine Neoplasia Syndromes: A Comprehensive Imaging Review. ( 27153782 )
2016
23
Recurrent hyperparathyroidism due to proliferation of autotransplanted parathyroid tissue in a multiple endocrine neoplasia type 2A patient. ( 27617256 )
2016
24
Pituitary Prolactinoma Imaged by 99mTc-Sestamibi SPECT/CT in a Multiple Endocrine Neoplasia Type 1 Patient. ( 26828146 )
2016
25
Imaging in multiple endocrine neoplasia type 1: recent studies show enhanced sensitivities but increased controversies. ( 26834963 )
2016
26
Novel multiple endocrine neoplasia type 1 variations in patients with sporadic primary hyperparathyroidism. ( 27366707 )
2016
27
A Possible New Multiple Endocrine Neoplasia Mutation in a Patient with a Prototypic Multiple Endocrine Neoplasia Presentation. ( 26989398 )
2016
28
Cutaneous lichen amyloidosis in multiple endocrine neoplasia. ( 26813904 )
2016
29
Pasireotide Therapy of Multiple Endocrine Neoplasia Type 1-Associated Neuroendocrine Tumors in Female Mice Deleted for an Men1 Allele Improves Survival and Reduces Tumor Progression. ( 26990064 )
2016
30
Multiple Endocrine Neoplasia: A Genetically Diverse Group of Familial Tumor Syndromes. ( 27617149 )
2016
31
Efficacy and Long-Term Safety of Everolimus in Pancreatic Neuroendocrine Tumor Associated with Multiple Endocrine Neoplasia Type I: Case Report. ( 27710978 )
2016
32
Characteristics of chronic megacolon among patients diagnosed with multiple endocrine neoplasia type 2B. ( 27403312 )
2016
33
Clinical and Genetic Analysis of Multiple Endocrine Neoplasia Type 1-Related Primary Hyperparathyroidism in Chinese. ( 27846313 )
2016
34
Perioperative Severe Hypotension in a Patient with Multiple Endocrine Neoplasia Type IIb and Bilateral Adrenalectomies: Time to Review the Evidence for Stress Dose Steroids. ( 27900224 )
2016
35
Notalgia Paresthetica and Multiple Endocrine Neoplasia Syndrome 2A: A Case Report. ( 27396529 )
2016
36
Multiple endocrine neoplasia phenocopy revealed as a co-occurring neuroendocrine tumor and familial hypocalciuric hypercalcemia type 3. ( 27761240 )
2016
37
Multiple endocrine neoplasia type 1 with anterior mediastinal parathyroid adenoma: successful localization using Tc-99m sestamibi SPECT/CT. ( 27904855 )
2016
38
Multiple Endocrine Neoplasia Type 1 Presenting as Hypoglycemia due to Insulinoma. ( 27247513 )
2016
39
Multiple endocrine neoplasia similar to human subtype 2A in a dog: Medullary thyroid carcinoma, bilateral pheochromocytoma and parathyroid adenoma. ( 27822452 )
2016
40
Reoperative Surgery in Patients with Multiple Endocrine Neoplasia Type 1 Associated Primary Hyperparathyroidism. ( 27464610 )
2016
41
The RET E616Q Variant is a Gain of Function Mutation Present in a Family with Features of Multiple Endocrine Neoplasia 2A. ( 27704398 )
2016
42
Operation for insulinomas in multiple endocrine neoplasia type 1: When pancreatoduodenectomy is appropriate. ( 27863775 )
2016
43
Pituitary adenoma associated with pheochromocytoma/paraganglioma: A new form of multiple endocrine neoplasia. ( 27639663 )
2016
44
Clinical Features, Treatments, and Outcomes of Patients with Thymic Carcinoids and Multiple Endocrine Neoplasia Type 1 Syndrome at MD Anderson Cancer Center. ( 27311764 )
2016
45
Multiple endocrine neoplasia type 2 kindred with novel tandem RET mutations: Case report with an applied in silico mutational tolerance analysis. ( 26876062 )
2016
46
Unilateral Clearance for Primary Hyperparathyroidism in Selected Patients with Multiple Endocrine Neoplasia Type 1. ( 27402205 )
2016
47
Local recurrence of pheochromocytoma in multiple endocrine neoplasia type 2A: a diagnostic and therapeutic challenge. ( 27014456 )
2016
48
In Vivo Confocal Microscopic Architecture of Corneal Nerves in a Case of Multiple Endocrine Neoplasia Type 2b. ( 27994400 )
2016
49
Parathyroid morphology and menin stainingA in multiple endocrine neoplasia type 1 (MEN 1). ( 27773149 )
2016
50
Assessing for multiple endocrine neoplasia type 1 in patients evaluated for Zollinger-Ellison Syndrome - clues to a safer diagnostic process. ( 28011308 )
2016

Variations for Multiple Endocrine Neoplasia

ClinVar genetic disease variations for Multiple Endocrine Neoplasia:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 RET NM_020630.4(RET): c.2410G> T (p.Val804Leu) single nucleotide variant Pathogenic rs79658334 GRCh37 Chromosome 10, 43614996: 43614996

Expression for Multiple Endocrine Neoplasia

Search GEO for disease gene expression data for Multiple Endocrine Neoplasia.

Pathways for Multiple Endocrine Neoplasia

Pathways related to Multiple Endocrine Neoplasia according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 11.77 CALCA NF1 PRKAR1A RET
2 10.74 GDNF RET
3 10.48 CDKN1B NF1 RET

GO Terms for Multiple Endocrine Neoplasia

Cellular components related to Multiple Endocrine Neoplasia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 mitochondrial respiratory chain complex II, succinate dehydrogenase complex (ubiquinone) GO:0005749 8.96 SDHB SDHC
2 respiratory chain complex II GO:0045273 8.62 SDHB SDHC

Biological processes related to Multiple Endocrine Neoplasia according to GeneCards Suite gene sharing:

(show all 14)
id Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.67 CDKN1B MEN1 NF1 VHL
2 metanephros development GO:0001656 9.54 GDNF NF1
3 tricarboxylic acid cycle GO:0006099 9.52 SDHB SDHC
4 aerobic respiration GO:0009060 9.51 SDHB SDHC
5 neural crest cell migration GO:0001755 9.49 GDNF RET
6 peripheral nervous system development GO:0007422 9.48 GDNF NF1
7 negative regulation of cyclin-dependent protein serine/threonine kinase activity GO:0045736 9.46 CDKN1B MEN1
8 negative regulation of osteoclast differentiation GO:0045671 9.43 CALCA NF1
9 response to pain GO:0048265 9.4 CALCA RET
10 sympathetic nervous system development GO:0048485 9.32 GDNF NF1
11 positive regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001241 9.26 NF1 RET
12 positive regulation of adenylate cyclase activity GO:0045762 9.16 CALCA NF1
13 enteric nervous system development GO:0048484 8.96 GDNF RET
14 MAPK cascade GO:0000165 8.92 GDNF MEN1 NF1 RET

Sources for Multiple Endocrine Neoplasia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....